Building on the huge success of monoclonal antibody therapeutics, the next generation of antibody-based products such as Antibody Drug Conjugate (ADC) and Bispecific Antibody (BsAb) is now opening up new opportunities.
The global market for Next Generation Antibody Therapeutics is estimated to increase from US$ 9392.2 million in 2021 to reach US$ 38470 million by 2028, exhibiting a CAGR of 22.3% during 2022-2028. Keeping in mind the uncertainties of COVID-19 and Russia-Ukraine War, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Global key players of next generation antibody therapeutics include Roche, Seagen, Amgen, Pfizer, Takeda, etc. The top two players hold a share over 70%. North America is the largest market, has a share about 65%, followed by Europe and Asia-Pacific, with share 16% and 15%, separately. In terms of product type, Antibody Drug Conjugate (ADC) is the largest segment, occupied for a share of 60%, and in terms of application, Cancer has a share about 66 percent.
Report Coverage
This latest report provides a deep insight into the global Next Generation Antibody Therapeutics market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, value chain analysis, etc.
This report aims to provide a comprehensive picture of the global Next Generation Antibody Therapeutics market, with both quantitative and qualitative data, to help readers understand how the Next Generation Antibody Therapeutics market scenario changed across the globe during the pandemic and Russia-Ukraine War.
The base year considered for analyses is 2021, while the market estimates and forecasts are given from 2022 to 2028. The market estimates are provided in terms of revenue in USD millions.
Market Segmentation:
The study segments the Next Generation Antibody Therapeutics market and forecasts the market size by Type (Antibody Drug Conjugate (ADC) and Bispecific Antibody (BsAb),), by Application (Cancer, Haemophilia and Other Non-Cancer Diseases,), and region (APAC, Americas, Europe, and Middle East & Africa).
Segmentation by type
Antibody Drug Conjugate (ADC)
Bispecific Antibody (BsAb)
Segmentation by application
Cancer
Haemophilia
Other Non-Cancer Diseases
Segmentation by region
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
Major companies covered
Roche
Amgen
Pfizer
Takeda
Daiichi Sankyo
Seagen
Astellas
Immunomedics
GSK
Immunocore
ADC Therapeutics
Chapter Introduction
Chapter 1: Scope of Next Generation Antibody Therapeutics, Research Methodology, etc.
Chapter 2: Executive Summary, global Next Generation Antibody Therapeutics market size and CAGR, Next Generation Antibody Therapeutics market size by region, by type, by application, historical data from 2017 to 2022, and forecast to 2028.
Chapter 3: Next Generation Antibody Therapeutics revenue, global market share, and industry ranking by company, 2017-2022
Chapter 4: Global Next Generation Antibody Therapeutics revenue by region and by country. Country specific data and market value analysis for the U.S., Canada, Europe, China, Japan, South Korea, Southeast Asia, India, Latin America and Middle East & Africa.
Chapter 5, 6, 7, 8: Americas, APAC, Europe, Middle East & Africa, revenue segment by country, by type, and application.
Chapter 9: Analysis of the current market trends, market forecast, opportunities and economic trends that are affecting the future marketplace
Chapter 10: Manufacturing cost structure analysis
Chapter 11: Sales channel, distributors, and customers
Chapter 12: Global Next Generation Antibody Therapeutics market size forecast by region, by country, by type, and application
Chapter 13: Comprehensive company profiles of the leading players, including Roche, Amgen, Pfizer, Takeda, Daiichi Sankyo, Seagen, Astellas, Immunomedics and GSK, etc.
Chapter 14: Research Findings and Conclusion